))
ONCOLOGY: Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
Archived series ("Inactive feed" status)
When?
This feed was archived on June 29, 2019 01:11 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 151341652 series 1024717
Content provided by Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Audio Journal of Oncology, December 9th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston REFERENCE: ABSTRACT 734, ASH 2007 New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.
…
continue reading
106 episodes
Share
